๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders

โœ Scribed by Mark Forrest Gordon; Rolando Diaz-Olivo; Ann L. Hunt; Dr. Stanley Fahn

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
478 KB
Volume
8
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

โœฆ Synopsis

Abstract

We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino Xโ€linked dystonia with parkinsonism, painful legs and moving toes, and stiffโ€person syndrome. Milacemide was initiated at a dose of 2,400 mg/ day, orally, and increased gradually to a maximum of 4,800 mg/ day. No clearโ€cut observable improvement occurred. There were no serious adverse effects.

๐Ÿ“œ SIMILAR VOLUMES

A therapeutic trial of milacemide in myo
A therapeutic trial of milacemide in myoclonus and the stiff-person syndrome
โœ P. Brown; P. D. Thompson; J. C. Rothwell; B. L. Day; Prof. C. D. Marsden ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 269 KB ๐Ÿ‘ 1 views

We investigated the therapeutic effects of milacemide in seven patients with myoclonus and three patients with the stiff-person syndrome in an open-label trial. Milacemide was initiated at 800 mg/day and was gradually increased to a maximum dosage of 2,400 mg/day. No significant improvement occurred

Diagnostic agreement in patients with ps
Diagnostic agreement in patients with psychogenic movement disorders
โœ Francesca Morgante; Mark J. Edwards; Alberto J. Espay; Alfonso Fasano; Pablo Mir ๐Ÿ“‚ Article ๐Ÿ“… 2012 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 91 KB

## Abstract ## Background: The reliability and applicability of published diagnostic criteria for psychogenic movement disorders (PMDs) have never been examined. ## Methods: Eight movement disorder and six general neurologists rated 14 patients diagnosed with PMD and 14 patients diagnosed with o

Electrophysiology of the corticomotoneur
Electrophysiology of the corticomotoneurone pathways in patients with movement disorders
โœ P. D. Thompson; J. P. R. Dick; B. L. Day; J. C. Rothwell; A. Berardelli; T. Kach ๐Ÿ“‚ Article ๐Ÿ“… 1986 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 316 KB

The corticomotoneurone pathways were examined in 21 patients with movement disorders, using the technique of percutaneous electrical stimulation of the motor cortex. Conduction in these pathways was assessed by measuring the latency to onset of electromyographic activity in the muscles of the upper

Neuropsychiatric assessment of Gilles de
Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders
โœ Jaime Kulisevsky; Irene Litvan; Marcelo L. Berthier; Berta Pascual-Sedano; Jane ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 49 KB ๐Ÿ‘ 1 views

## Abstract The role of the basal ganglia in conditions with coโ€occurring movement disorders and neuropsychiatric symptoms is not well known. It has been hypothesized that hyperkinesia โ€disinhibited behaviors and hypokinesiaโ€inhibited behaviors result from an imbalance between the direct and indire

Clinical characteristics of 49 patients
Clinical characteristics of 49 patients with psychogenic movement disorders in a tertiary clinic in Turkey
โœ Sibel Ertan; Derya Uluduz; Sibel ร–zekmekรงi; Gรผnes Kiziltan; Turan Ertan; Cengiz ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 457 KB ๐Ÿ‘ 1 views

## Abstract Patients admitted to movement disorders outpatient unit at a university hospital between January 2002 and June 2007 were screened for psychogenic movement disorders (PMDs). Out of 1,743 patients, 49 patients (2.8%), including four children, were diagnosed to have PMDs. Women to men rati